A- A A+

Prevalence of HIV, Hepatitis C and its related risk behaviours among women who inject drugs in the Kathmandu Valley, Nepal: a cross-sectional study. 

Damas J, Storm M, Pandey LR, Marrone G, Deuba K. 

Ther Adv Infect Dis. 2021 Dec 3;8:20499361211062107. doi: 10.1177/20499361211062107. PMID: 34881024; PMCID: PMC8646840.


Hepatitis C Vaccination: Where We Are and Where We Need to Be. 

Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. 

Pathogens. 2021 Dec 14;10(12):1619. doi: 10.3390/pathogens10121619. PMID: 34959574; PMCID: PMC8705661.


Hepatitis C virus DNA vaccines: a systematic review. 

Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Hedayat Yaghoobi M, Hashempour T, Mozhgani SH. 

Virol J. 2021 Dec 13;18(1):248. doi: 10.1186/s12985-021-01716-8. PMID: 34903252; PMCID: PMC8667529.


HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

Semmler, Georg et al.

Journal of Hepatology, Volume 0, Issue 0 


INPUD Summary Report: WHO Key Populations' Values & Preferences for HIV, Hepatitis and STIs Services 


Over the last several months INPUD has collaborated with the World Health Organization (WHO) Department for Global HIV, Hepatitis and STI Programmes on a global qualitative study examining the values and preferences of key populations, including people who inject drugs, for HIV, Hepatitis and STIs services. The findings of this study will inform the update of the WHO 2016 Consolidated Guidelines for HIV prevention, diagnosis, treatment and care for key populations. These Guidelines will be used to inform countries on the design and implementation of health packages for key populations, making it extremely important that they take into account the specific values and preferences of each key population included in the study (people who inject drugs, gay and bisexual men and other men who have sex with men, female, male and trans sex workers and trans people). (INPUD - The International Network of People who Use Drugs, 2021)


Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs. 

Durand M, Nagot N, Nhu QBT, Vallo R, Thuy LLT, Duong HT, Thanh BN, Rapoud D, Quillet C, Tran HT, Michel L, Tuyet TNT, Hai OKT, Hai VV, Feelemyer J, Perre PV, Jarlais DD, Minh KP, Laureillard D, Molès JP. 

J Clin Med. 2021 Oct 20;10(21):4824. doi: 10.3390/jcm10214824. PMID: 34768343; PMCID: PMC8584601.


Out-of-Hospital Treatment of Hepatitis C Increases Retention in Care among People Who Inject Drugs and Homeless Persons: An Observational Study.

Granozzi B, Guardigni V, Badia L, Rosselli Del Turco E, Zuppiroli A, Tazza B, Malosso P, Pieralli S, Viale P, Verucchi G. 

J Clin Med. 2021 Oct 26;10(21):4955. doi: 10.3390/jcm10214955. PMID: 34768474; PMCID: PMC8584608.


INHSU 2021 - Virtual conference - 13-15 October 2021 

Epidemiology and public health in hepatitis C, other infectious diseases, and the broader health of people who use drugs. (International Network on Health and Hepatitis in Substance Users, November 2021)


Erfolgreiche Hepatitis C-Therapie senkt die Notwendigkeit für Lebertransplantationen deutlich

Hannover, 12. November 2021 – Die Hepatitis C-Virusinfektion war bis vor Kurzem einer der häufigsten Gründe für eine Lebertransplantation. Die Erkrankung kann inzwischen jedoch bei fast allen Patienten in kurzer Zeit geheilt werden. Eine heute erscheinende Publikation mit Daten von hepatologischen Zentren, die am Deutschen Hepatitis C-Register der Deutschen Leberstiftung teilnehmen, zeigt, dass durch die aktuellen Behandlungsmöglichkeiten der Bedarf an Lebertransplantationen aufgrund von Hepatitis C deutlich gesunken ist. (Deutsche Leberstiftung, 12.11.2021)


Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. 

Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MA, Brégigeon-Ronot S, Morlat P, Billaud E, Piroth L, Naqvi A, Sogni P, Salmon D; ANRS CO13 HEPAVIH Cohort Study Group. 

HIV Med. 2021 Oct;22(9):791-804. doi: 10.1111/hiv.13127. Epub 2021 Jul 1. PMID: 34212476.


In Love With the Virus: Reducing Harms, Promoting Dignity, and Preventing Hepatitis C Through Graphic Narratives. 

Bartoszko A. 

Health Promot Pract. 2021 Oct 19:15248399211041075. doi: 10.1177/15248399211041075. Epub ahead of print. PMID: 34664516.


Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.

Dhiman RK, Grover GS, Premkumar M, Roy A, Taneja S, Duseja A, Arora S; MMPHCRF Investigators. 

EClinicalMedicine. 2021 Oct 17;41:101148. doi: 10.1016/j.eclinm.2021.101148. PMID: 34712928; PMCID: PMC8529203.


Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. 

Akiyama MJ, Riback L, Reeves JD, Lie YS, Agyemang L, Norton BL, Arnsten JH, Litwin AH. 

Open Forum Infect Dis. 2021 Sep 30;8(10):ofab474. doi: 10.1093/ofid/ofab474. PMID: 34692891; PMCID: PMC8530260.


Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R). 

Schlevogt B, Boeker KHW, Mauss S, Klinker H, Heyne R, Link R, Simon KG, Sarrazin C, Serfert Y, Manns MP, Wedemeyer H. 

Biomedicines. 2021 Oct 19;9(10):1495. doi: 10.3390/biomedicines9101495. PMID: 34680612; PMCID: PMC8533115.


Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in South Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. 

Kim KA, Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Ki M, Choi HY, Paik DH, Jeong SH. 

Epidemiol Health. 2021 Oct 6:e2021077. doi: 10.4178/epih.e2021077. Epub ahead of print. PMID: 34645207.


The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. 

Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, et al. (2021) 

PLoS ONE 16(10): e0258143. doi.org/10.1371/journal.pone.0258143


Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. 

Fraser H, Stone J, Wisse E, Sambu V, Mfisi P, Duran IJ, Soriano MA, Walker JG, Makere N, Luhmann N, Kafura W, Nouvellet M, Ragi A, Mundia B, Vickerman P. 

J Int AIDS Soc. 2021 Oct;24(10):e25817. doi: 10.1002/jia2.25817. PMID: 34661964; PMCID: PMC8522890.


Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, 

Falcato L, Bernardini C, Bruggmann P. 

Switzerland. Int J Drug Policy. 2021 Sep 9:103434. doi: 10.1016/j.drugpo.2021.103434. Epub ahead of print. PMID: 34511311.



Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. 

Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. 

Int J Drug Policy. 2021 Apr 11:103247. doi: 10.1016/j.drugpo.2021.103247. Epub ahead of print. PMID: 33853727.


Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. 

Harris M, Guy D, Picchio CA, White TM, Rhodes T, Lazarus JV. 

Int J Drug Policy. 2021 Jul 11:103320. doi: 10.1016/j.drugpo.2021.103320. Epub ahead of print. PMID: 34261587.


Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? 

Lanièce Delaunay C, Godin A, Kronfli N, Panagiotoglou D, Cox J, Alary M, Klein MB, Maheu-Giroux M. 

Int J Drug Policy. 2021 Jun 29:103343. doi: 10.1016/j.drugpo.2021.103343. Epub ahead of print. PMID: 34215459.


Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. 

Tun GS, Gleeson D, Dube A, Al-Joudeh A. 

J Hepatol. 2021 Oct 4:S0168-8278(21)02093-6. doi: 10.1016/j.jhep.2021.09.031. Epub ahead of print. PMID: 34619252; PMCID: PMC8491984.


Hepatitis C reinfection in former and active injecting drug users in Belgium. 

Busschots, D., Bielen, R., Koc, Ö.M. et al.

Harm Reduct J 18, 102 (2021). doi.org/10.1186/s12954-021-00552-x


Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. 

Foschi FG, Borghi A, Grassi A, Lanzi A, Speranza E, Vignoli T, Napoli L, Olivoni D, Sanza M, Polidori E, Greco G, Bassi P, Cristini F, Ballardini G, Altini M, Conti F, On Behalf Of Mith Group. 

J Clin Med. 2021 Sep 3;10(17):4001. doi: 10.3390/jcm10174001. PMID: 34501448; PMCID: PMC8432451.


How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study. 

Heard E, Smirnov A, Massi L, Selvey LA. 

Aust J Gen Pract. 2021 Oct;50(10):716-721. doi: 10.31128/AJGP-03-21-5899. PMID: 34590083.


Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care. 

Epstein RL, Moloney C, Garfinkel J, Saia K, Wachman EM, Lodi S, Pelton SI. 

Hepatol Commun. 2021 Sep;5(9):1543-1554. doi: 10.1002/hep4.1748. Epub 2021 Jul 1. PMID: 34510828; PMCID: PMC8435278.


Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care. 

Epstein RL, Moloney C, Garfinkel J, Saia K, Wachman EM, Lodi S, Pelton SI. Enhancing 

Hepatol Commun. 2021 Sep;5(9):1543-1554. doi: 10.1002/hep4.1748. Epub 2021 Jul 1. PMID: 34510828; PMCID: PMC8435278.


Hepatitis C Virus Reactivation Following COVID-19 Vaccination - A Case Report. 

Lensen R, Netea MG, Rosendaal FR. 

Int Med Case Rep J. 2021 Aug 29;14:573-576. doi: 10.2147/IMCRJ.S328482. PMID: 34512037; PMCID: PMC8412816.


Australien. Rapid hepatitis C testing to be rolled out at dozens of sites nationwide

A new rapid test for hepatitis C will be rolled out at dozens of drug treatment clinics, prisons and needle exchange services across Australia to help eliminate a disease that kills 740 people every year. (Sydney Morning Herald, Australien, 19.09.2021)


MEDIZINREPORT: Studien im Fokus

Hepatitis C: Nach effektiver antiviraler Therapie sinken die Risiken für KHK und für Schlaganfall

Siegmund-Schultze, Nicola

Dtsch Arztebl 2021; 118(35-36): A-1585 / B-1316